Definitions Articles

NASH covers a wide spectrum of disease severity and NAFLD is increasingly common worldwide ☂ and has become the principal cause of chronic liver disease.

Surveying Stigma: MAFLD’s Nomenclature from Patient and Provider Perspectives

Authors: Younossi ZM et al.
Published in Journal of Hepatology (November 2023)
Non-alcoholic fatty liver disease (NAFLD) is estimated to affect 38% of adults worldwide, a statistic which is expected to increase with the rise of type 2 diabetes and obesity.
Read MoreSurveying Stigma: MAFLD’s Nomenclature from Patient and Provider Perspectives

Cardiovascular Disease in MASLD Patients: Mitigating Risks

Authors: Mellemkjær A et al.
Published in European Journal of Internal Medicine (November 2023)
The term metabolic dysfunction-associated steatotic liver disease (MASLD) has recently been proposed as an alternative to non-alcoholic fatty liver disease (NAFLD)’s exclusionary nomenclature.
Read MoreCardiovascular Disease in MASLD Patients: Mitigating Risks

The new paradigm of cardiometabolic syndrome: a review

Authors: Khan AR, Salama AH, Aleem Z, et al.
Published in Cureus (September 2023)
Cardiometabolic syndrome (CMS) involves a complex interplay of many issues, involving obesity, metabolic dysregulation, cardiovascular disease, insulin resistance and more. This condition extends to clinical implications including non-alcoholic fatty liver disease (NAFLD) as well as cancer and sleep apnoea.
Read MoreThe new paradigm of cardiometabolic syndrome: a review

Liver Stiffness and All-Cause Mortality in NAFLD Patients: Is There an Independent Link?

Authors: Ciardullo S, Muraca E, Zerbini F et al.
Published in Liver International (September 2023)
Liver-related events contribute to a small proportion of mortality within the collective cohort of patients with non-alcoholic fatty liver disease (NAFLD).
Read MoreLiver Stiffness and All-Cause Mortality in NAFLD Patients: Is There an Independent Link?

“Refining Strategies And Redefining Success”: Lessons Learned From Failed Nash Trials

Authors: Francque SM, Noureddin M, Krag A
Published in Clinical Gastroenterology and Hepatology (August 2023)
Despite ample preclinical evidence of numerous compounds’ efficacy and over 15 years of clinical trials, no pharmacotherapy has yet been approved to treat non-alcoholic steatohepatitis (NASH)
Read More“Refining Strategies And Redefining Success”: Lessons Learned From Failed Nash Trials

Understanding Nash: Symptoms, Detection, And Treatment

Authors: Basu M, Noureddin M, Clark JM
Published in Mayo Clinic Proceedings (September 2022)
Nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease (NAFLD), has seen a consistent rise in prevalence in recent years owing to the global epidemics of obesity and type 2 diabetes (T2D)
Read MoreUnderstanding Nash: Symptoms, Detection, And Treatment

An exploration of MAFLD’s clinical utility

Authors: Ramírez-Mejía MM, Xingshun Q, Abenavoli L et al
Published in Annals of Hepatology (July 2023)
In 2020, a group of international experts proposed that non-alcoholic fatty liver disease (NAFLD) be renamed to metabolic dysfunction-associated fatty liver disease (MAFLD).
Read MoreAn exploration of MAFLD’s clinical utility

MASLD: A New Fatty Liver Disease Nomenclature?

Authors: Rinella ME, Lazarus JV, Ratziu V et al.
Published in Journal of Hepatology (June 2023)
Disease awareness, patient stratification, diagnosis, and access to care are all helped or hindered by a pathology’s nomenclature. Indeed, the language used to name and identify a disease has the power to create or intensify social stigma, marginalise subsets of a patient population, and perpetuate health inequalities.
Read MoreMASLD: A New Fatty Liver Disease Nomenclature?

Costs of Care for Non-Alcoholic Steatohepatitis in the United States: A Review

Authors: Tapper EB, Bonafede M, Fishman J, et al.
Published in J Med Econ 2023
The rising healthcare costs of NASH highlight the need for early intervention. Higher FIB-4 scores correlate with increased healthcare expenses. Early-stage intervention can reduce the burden on patients and the healthcare system.
Read MoreCosts of Care for Non-Alcoholic Steatohepatitis in the United States: A Review

Non-metabolic/-Alcoholic Fatty Liver Disease: A Review

Authors: Allende DS & Kleiner DE
Published in Hum Pathol 2023
Fatty liver disease can be caused by many different autosomal recessive diseases. One includes Wilson’s disease, a condition which leads to abnormal copper accumulation in multiple organs. Cirrhosis is common in up to 30% of cases, as well as steatosis and steatohepatitis. Cystic fibrosis is another example, where steatosis is common and liver disease occurs in 0.1-3.6% of patients. Furthermore, alpha-1-antitrypsin deficiency and lysosomal acid lipase deficiency have been linked to steatosis accumulation, although have little research into their pathogenesis.
Read MoreNon-metabolic/-Alcoholic Fatty Liver Disease: A Review

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES